Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma
Plain-language summary
This trial is testing EBV-specific T cells (immune cells trained to attack Epstein-Barr virus in lymphoma cells) for patients with extranodal NK/T-cell lymphoma (ENKTL) at various stages of their disease. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Patients are randomly assigned to different treatment groups. This trial does not currently have sites in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Age 18 Years to 75 Years years
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Sintilimab+Pegaspargase (DRUG): 1. Sintilimab, 200mg intravenous drip, on day 1; 2. pegaspargase, 2000U/m\^2, capped at 3750U, intramuscular, day 1; | P-GemOx (DRUG): 1. pegaspargase 2000U/m\^2, capped at 3750U on day 1, intramuscular; 2. gemcitabine 1.0g/m\^2 on day 1 and day 8, intravenous drip; 3. oxaliplatin 130mg/m\^2 on day 1, intravenous drip | GELAD (DRUG): 1. gemcitabine 1.0g/m\^2 on day 1, intravenous drip; 2. etoposide 60mg/m\^2 on day 1-3, intravenous drip; 3. pegaspargase 2000U/m\^2, capped at 3750U on day 1,intramuscular; 4. dexamethasone 20mg on day 1-4, intravenous drip. | IMRT (RADIATION): Intensity modulated radiotherapy (50-56Gy)
Sintilimab+Pegaspargase, P-GemOx, GELAD, IMRT
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details